Atypical Antipsychotic Use in Pregnancy: A Retrospective Review

Arch Womens Ment Health. 2009 Feb;12(1):53-7. doi: 10.1007/s00737-008-0044-3. Epub 2009 Jan 10.

Abstract

To determine the prevalence of use of atypical antipsychotics in pregnancy and describe infant outcomes associated with these exposures. A retrospective chart review of all pregnant women presenting at our medical center, from the years 1993 to 2007, was conducted. 30,092 total deliveries during that time period were identified. 16 mothers were treated with atypical antipsychotics during their pregnancy. The medical charts of the infants exposed to atypical antipsychotics during pregnancy were reviewed to determine their outcomes, including gestational age, birth weight, and malformations. Only 16 (0.053%) of the women took an atypical antipsychotic at some point during the antenatal period. Average gestational age was 37 5/7 weeks with a standard deviation of 2.54 days. Average birth weight was 3,188 g with a standard deviation of 615 g, which is appropriate for early gestational age. One (6.25%) major malformation was noted. Additional studies need to be completed regarding the effect of atypical antipsychotic use in pregnancy and outcomes related to gestational age, birth weight and malformations.

MeSH terms

  • Abnormalities, Drug-Induced
  • Antipsychotic Agents / adverse effects*
  • Birth Weight
  • Female
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Maternal Exposure*
  • Medical Audit
  • Pregnancy
  • Pregnancy Outcome
  • Prenatal Exposure Delayed Effects / chemically induced*
  • Retrospective Studies

Substances

  • Antipsychotic Agents